A new Covid-19 variant, BA.3.2, has been identified spreading across the United States, with cases reported in 25 states. The Centers for Disease Control and Prevention (CDC) confirmed its presence in clinical samples, wastewater, and among travelers, raising concerns about its potential to evade protection from existing vaccines.
Part 1: Immediate Action & Core Facts
The BA.3.2 variant was first detected in South Africa in 2024 and later in the U.S. in June 2025 in a traveler from the Netherlands. By September 2025, it began surging and has since been reported in 23 countries. In the U.S., it has been found in nasal swabs of four American travelers, clinical samples from five patients in four unidentified states, and 132 wastewater samples across more than 20 states, suggesting widespread circulation.
The CDC cautioned that it is not yet clear whether BA.3.2 causes more severe illness or significantly impacts the U.S. healthcare system. However, researchers warn that the variant is genetically distinct from the JN.1 lineages currently targeted by vaccines, which could necessitate updates to vaccine formulations.
Part 2: Deeper Dive & Context
Origins and Evolution
BA.3.2 is descended from the Omicron variant and shares evolutionary similarities with BA.2.86, which later evolved into JN.1, the dominant U.S. variant in 2024. The new strain carries 70 to 75 genetic changes in its spike protein, a key part of the virus that allows it to enter human cells. These mutations raise concerns about vaccine efficacy, as current vaccines are designed to target JN.1 subvariants.
Detection and Spread
The variant was first identified in November 2024 in South Africa and has since been detected in 140 samples collected in the U.S. as of February 11, 2026. Wastewater surveillance has been instrumental in tracking its spread, with samples collected from airplanes and multiple states indicating broader transmission than clinical cases alone.
Public Health Response
The CDC has not yet issued specific guidance on BA.3.2 but is monitoring its spread closely. Researchers emphasize the need for continued surveillance and potential vaccine updates to address the variant’s genetic distinctiveness. Public health officials urge vigilance but note that the severity of illness remains uncertain.
Global Context
BA.3.2 has been reported in 23 countries, highlighting its international spread. The variant’s emergence underscores the ongoing challenge of Covid-19 evolution and the need for adaptive public health strategies.